Alloreactive T-cell receptor (TCR) (TCR)

Alloreactive T-cell receptors (TCRs) are membrane-bound heterodimeric proteins, typically composed of alpha and beta chains, that recognize non-self (allogeneic) human leukocyte antigen (HLA) molecules (NIH, 2021). These receptors are central to the immune system's ability to distinguish between self and non-self, a process fundamental to transplant rejection and the efficacy of certain cancer immunotherapies (Frontiers in Immunology, 2019). In the context of fusion cell vaccines—where allogeneic dendritic cells are fused with autologous tumor cells—alloreactive TCRs recognize the allogeneic HLA components of the fusion, which acts as a potent adjuvant to stimulate a robust anti-tumor immune response (ResearchGate, 2020). This recognition triggers a signaling cascade through the associated CD3 complex, leading to T-cell proliferation, cytokine release, and the targeted lysis of cells expressing the recognized antigens (NIH, 2018). While alloreactive TCRs are the primary mediators of graft-versus-host disease (GvHD) in hematopoietic stem cell transplantation, they are also being harnessed in TCR-engineered T-cell (TCR-T) therapies to target specific malignancies (OSU, 2023). Drugs that modulate these receptors, such as calcineurin inhibitors and monoclonal antibodies targeting CD3 or IL-2 receptors, are essential for managing alloreactivity in clinical settings (StatPearls, 2023). The interaction between alloreactive TCRs and allogeneic HLA on fusion cells represents a unique therapeutic intersection where allorecognition is intentionally induced to overcome tumor-mediated immunosuppression.

Other names

T-cell receptorAllo-HLA-restricted TCRAllospecific TCRAlloreactive TCR

Recognition of allogeneic HLA-peptide complexes on the surface of target cells, leading to the activation of the CD3 signaling complex and subsequent T-cell effector functions, including cytokine production and cytotoxicity (NIH, 2021; Frontiers in Immunology, 2019).